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The RNA-guided nuclease Cas9 can be reengineered as a programmable transcription factor. 
However, modest levels of gene activation have limited potential applications. We describe 
an improved transcriptional regulator through the rational design of a tripartite activator, 
VP64-p65-Rta (VPR), fused to nuclease-null Cas9. We demonstrate its utility in activating 
endogenous coding and non-coding genes, targeting several genes simultaneously and 
stimulating neuronal differentiation of human induced pluripotent stem cells (iPSCs).
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Cas9 is an RNA-guided endonuclease that is directed to a specific DNA sequence through 
complementarity between the associated guide RNA (gRNA) and its target locus1,2. Cas9 
can be directed to nearly any arbitrary sequence with a gRNA, requiring only a short 
protospacer adjacent motif (PAM) site proximal to the target3–5. Through mutational 
analysis, variants of Cas9 have been generated that lack endonucleolytic activity but retain 
the capacity to interact with DNA2,6,7. These nuclease-null (dCas9) variants have been 
subsequently functionalized with effector domains such as transcriptional activation 
domains (ADs), enabling Cas9 to serve as a tool for cellular programming at the 
transcriptional level6,8–10. The ability to program the robust induction of expression at a 
specific target within its native chromosomal context would provide a transformative tool 
for myriad applications, including the development of therapeutic interventions, genetic 
screening, activation of endogenous and synthetic genetic circuits, and the induction of 
cellular differentiation11–13.
In natural systems, transcriptional initiation occurs through the coordinated recruitment of 
necessary machinery by a number of locally concentrated transcription factor activation 
domains (ADs). As a result, we hypothesized that the tandem fusion of multiple ADs would 
increase transcriptional activation by mimicking the natural cooperative recruitment process. 
Towards this goal a series of more than 20 candidate effectors with known transcriptional 
roles were fused to the C terminus of Streptococcus pyogenes (SP)-dCas9, and their potency 
was assessed by a fluorescent reporter assay performed in human HEK 293T cells 
(Supplementary Figs. 1 and 2)14.
Of the hybrid proteins tested, dCas9-VP64, dCas9-p65, and dCas9-Rta showed the most 
meaningful reporter induction. Nonetheless, neither the p65 nor the Rta hybrids were 
stronger activators than the commonly used dCas9-VP64 protein. Taking dCas9-VP64 as a 
starting scaffold, we subsequently extended the C-terminal fusion with the addition of either 
p65 or Rta. As predicted, these bipartite fusions exhibited increased transcriptional activity. 
Further improvement was observed when both p65 and Rta were fused in tandem to VP64, 
generating a hybrid VP64-p65-Rta tripartite activator (hereon referred to as VPR) 
(Supplementary Fig. 3).
To begin characterizing VPR, we verified the importance of each of its constituent domains 
(VP64, p65, and Rta) by replacing the respective member with mCherry, and measuring the 
resulting protein’s activity by reporter assay. All fusions containing mCherry exhibited 
decreased activity, demonstrating the essentiality of all three domains (Supplementary Fig. 
4). We further validated the importance of domain order by shuffling the positions of the 
three domains, generating all possible non-repeating dCas9 fusion proteins. Evaluation of 
the VPR permutations confirmed that the original ordering was indeed optimal 
(Supplementary Fig. 5).
Given the potency of our SP-dCas9-VPR fusion, we investigated whether the VPR construct 
would exhibit similar potency when fused to other DNA-binding scaffolds. Fusion of VPR 
to a nuclease-null Streptococcus thermophilus (ST1)-dCas9, a designer transcription 
activator like effector (TALE), or a zinc-finger protein allowed for an increase in activation 
relative to VP64 (Supplementary Fig. 6)15.
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Having performed initial characterization of our SP-dCas9-VPR fusion, we sought to assess 
its ability to activate endogenous coding and non-coding targets relative to VP64. To this 
end, we constructed three to four gRNAs against a set of factors related to cellular 
reprogramming, development, and gene therapy. When compared to the dCas9-VP64 
activator, dCas9-VPR showed 22 to 320 fold improved activation of endogenous targets 
(Fig. 1A). While VPR was able to induce each of our target genes to a much greater extent 
than VP64, a marked difference in the relative levels of gene induction between targets was 
observed. Furthermore, in accordance with previous studies16, we noted an inverse 
correlation between basal expression level and relative expression gain induced by dCas9 
activators (genes with high basal expression were less potently activated) (Supplementary 
Fig. 7).
To place our observed levels of activation within a biologically relevant context we 
compared dCas9-VPR activation in HEK 293T cells with the expression of the same gene 
within its native human tissue. Absolute comparisons in gene expression between in vitro 
cell lines and native tissues are difficult, but our preliminary analysis suggests that we were 
able to activate a number of our target genes to similar levels as in their native tissues 
(Supplementary Fig. 8).
Cas9 enables multiplexed activation through the simple introduction of a collection of guide 
RNAs against a desired set of genes. To determine the efficiency of multi-gene targeting, we 
performed a pooled activation experiment simultaneously inducing four of our initially 
characterized genes: MIAT, NEUROD1, ASCL1, and RHOXF2. VPR allowed for robust 
multi-locus activation, exhibiting several-fold higher expression levels than VP64 across the 
panel of genes (Fig. 1B).
After demonstrating dCas9-VPR’s ability to robustly activate gene expression in human 
cells, we sought to further explore its versatility as a general tool for gene induction within 
alternate model systems. Expression of dCas9-VPR in Saccharomyces cerevisiae, 
Drosophila melanogaster S2R+ cells, and Mus musculus Neuro-2A cells led to a range of 
improved activation from 5 to 300 fold over VP64 based activators (Supplementary Fig. 9).
The ability to selectively upregulate gene expression provides a powerful means to 
reprogram cellular identity for regenerative medicine and basic research purposes. Previous 
work has shown that the ectopic expression of several cDNAs promotes the differentiation 
of stem cells into multiple cell types. While such artificial induction often requires multiple 
factors, it was recently shown that exogenous expression of single transcription factors, 
Neurogenin2 (NGN2) or Neurogenic differentiation factor 1 (NEUROD1), is sufficient to 
promote differentiation of human iPS cells into induced neurons (iNeurons)17,18. While our 
previous attempts to generate iNeurons from iPS cells using dCas9-VP64-based activators 
were unsuccessful (data not shown), we were optimistic that the increased potency of VPR 
might induce sufficient expression of NGN2 and/or NEUROD1 protein to trigger 
differentiation.
Stable PGP1 iPS, doxycycline-inducible, dCas9-VP64 and dCas9-VPR cell lines were 
generated and transduced with lentiviral vectors containing a mixed pool of 30 gRNAs 
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directed against either NGN2 or NEUROD1. To determine differentiation efficiency, gRNA 
containing dCas9-AD iPS cell lines were cultured in the presence of doxycycline and 
monitored for phenotypic changes (Supplementary Figs. 10 and 11). We observed that VPR, 
in contrast to VP64, enabled rapid and robust differentiation of iPS cells into a neuronal 
phenotype. Additionally, these cells stained positively for the neuronal markers beta III 
tubulin and neurofilament 200 (Fig. 2A and Supplementary Fig. 12A, respectively). 
Subsequent quantification of the staining revealed that dCas9-VPR cell lines showed a 10 to 
37-fold improvement in the amount of iNeurons observed through upregulation of either 
NGN2 or NEUROD1 (Fig. 2B and Supplementary Fig. 12B). Analysis by qRT-PCR 
revealed a 10-fold and 18-fold increase in NGN2 and NEUROD1 mRNA expression levels, 
respectively, within dCas9-VPR cells over their dCas9-VP64 counterparts (Fig. 2C).
Over the past year there were a number of exciting advances in the field of Cas9-derived 
transcriptional activators. Two-component systems that rely on innovative gRNA 
modifications (e.g., synergistic activation mediator (SAM) and scaffold RNA (scRNA)) and 
epitope-based attachment systems (e.g., SUperNova (SunTag)) continue to push the limits of 
activator potency16,19,20. Notably, it was shown that the multimeric recruitment of even 
modestly effective activation domains (i.e., VP64 and p65) can lead to abundant increases in 
transcriptional output16,19,20. We believe that the rational selection and ordered fusion of 
individual activator domains provides an approach that is highly effective while eliminating 
the delivery and design complications generated by a two-component activator. In addition, 
as even modestly potent activation domains have exhibited marked improvement in activity 
when repeatedly recruited to a single dCas9 protein, we envision that our more potent VPR 
activator should lead to drastically improved activation if multiply recruited to a single 
dCas9 protein through technologies such as SAM, scRNA or SunTag.
Beyond the utility of VPR as a technological catalyst, we believe that our design process 
brings to light several important generalizations for future synthetic effectors, most notably 
the importance in screening large numbers of putative candidates and the critical role of 
domain order in the emergent synergy of multi-component fusions.
Online Materials and Methods
Vectors used and designed
Activation domains were cloned using a combination of Gibson and Gateway assembly or 
Golden Gate assembly methods. For experiments involving multiple activation domains, 
ADs were separated by short glycine-serine linkers. Activator sequences are listed in the 
Supplementary Data (vectors to be deposited in Addgene). All SP-dCas9 plasmids were 
based on Cas9m4-VP64 (Addgene #47319)6, ST1-dCas9 plasmids were based on M-ST1n-
VP64 (Addgene #48675)15. Sequences for gRNAs are listed in the supplementary 
information. gRNAs for endogenous human gene activation were selected to bind between 1 
and 1000 bp upstream of the transcriptional start site (TSS). gRNAs for iPSC differentiation 
to iNeurons, targeting NGN2 and NEUROD1, were selected to bind between 1 and 2000 
base pairs upstream of the transcriptional start site. All human gRNAs were expressed from 
either cloned plasmids (Addgene #41817)5 or integrated into the genome through lentiviral 
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delivery (plasmid SB700). Guide RNA sequences are listed within the Supplementary Data. 
Reporter targeting gRNAs were previously described (Addgene #48671 and #48672)6.
Mammalian cell culture and transfections
HEK 293T cells (gift from P. Mali, UCSD) and Neuro-2A cells (ATCC CCL-131), were 
maintained in high glucose Dulbecco’s Modified Eagle’s Medium (Invitrogen) 
supplemented with 10% FBS (Invitrogen) and penicillin/streptomycin (Invitrogen). Cells 
were maintained at 37°C and 5% CO2 in a humidified incubator and tested for mycoplasma 
yearly. Cells were transfected in 24-well plates seeded with 50,000 cells per well. 200ng of 
dCas9 activator, 10ng of gRNA and 60ng of reporter plasmid (when required) were 
delivered to each well with Lipofectamine 2000 (HEK 293T) or Lipofectamine 3000 
(Neuro-2A), according to manufacturer’s instructions. For multiplex activation, a 40ng mix 
of gRNAs was used, with a 10ng total amount of guide per each of the four gene targets. For 
example, if four guide RNAs were used against an individual target, 2.5ng of each guide 
RNA were combined, to obtain a 10ng mix for that target - then the four 10ng mixes were 
combined to prepare 40 ng total for transfection. Cells were grown 36–48 hours after 
transfection before being assayed using fluorescence microscopy, flow cytometry or lysed 
for RNA purification and quantification.
S. cerevisiae manipulation
Yeast strain W303 was used for all experiments. dCas9 activator constructs were cloned into 
vector pAG414-GPD (Addgene #14144)21. gRNAs (located between 100–200 bp upstream 
of the TSS) were expressed from the SNR52 promoter and cloned into the 2μ based 
pAG60-2u vector22. Cells were grown up overnight at 30°C in synthetic complete media 
lacking tryptophan and uracil. The following day cells were diluted 1:100 into 5mls of fresh 
media and grown for an additional 7 hours at 30°C. 2mls of culture was then spun down for 
RNA extraction.
Drosophila culture
Drosophila S2R+ cells were grown in Schneider’s medium (Invitrogen) supplemented with 
10% heat-inactivated FBS (JRH Biosciences) and penicillin/streptomycin (Sigma) at 25°C 
without CO2. Cells were transfected using Effectene Transfection Reagent (Qiagen) 
according to manufacturer’s instructions. Transfections were performed in 24 well plates 
and cells were seeded at 30,000 cells per well. 150ng of dCas9 activator and 50ng gRNAs 
were transfected and incubated for 3 days at 25°C before extraction of total RNA. Five 
gRNAs were transfected against each of the indicated target genes.
Fluorescence Reporter Assay
SP-dCas9 reporter assays were performed by targeting all dCas9-ADs with a single guide to 
a minimal CMV promoter, driving expression of a fluorescent reporter. Addgene plasmid 
#473206 was used to screen for novel ADs (Supplementary Figs. 1 and 2) or was altered to 
contain a sfGFP reporter gene instead of tdTomato (Supplementary Figs. 3B, 4 and 5). In 
addition, to control for transfection efficiency (Supplementary Figs. 3B, 4 and 5) an EBFP2 
expressing control plasmid was co-transfected at 25ng per well (EBFP2 plasmid was not co-
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transformed in Supplementary Fig. 2). To remove untransfected cells from the analysis, 
sfGFP fluorescence was only analyzed in cells with >103 EBFP2 expression (as determined 
by flow cytometry). For fusion of VPR to other programmable transcription factors (ST1-
dCas9, TALE, and zinc-finger protein) no EBFP2 plasmid was transfected. ST1-dCas9 
reporter assays were performed using the previously described tdTomato reporter with an 
appropriate PAM inserted upstream of the tdTomato coding region (Addgene #48678)15. 
The binding sequences for the zinc finger and TALE are TAATTANGGGNG and 
ACCTCATCAGGAACATGTT, respectively.
qRT-PCR analysis
Yeast RNA was extracted using the YeaStar kit (Zymogen), RNA from Drosophila S2R 
cells was extracted using Trizol (Life Technologies), and RNA from human cells was 
extracted using the RNeasy PLUS mini kit (Qiagen). Human tissue RNA was obtained from 
Life Technologies (Human Brain Total RNA (AM7962), Human Heart Total RNA 
(AM7966) and Human Testes Total RNA (AM7972)). 500ng of RNA was used with the 
iScript cDNA synthesis Kit (BioRad), and 0.5μl of cDNA was used for each qPCR reaction, 
utilizing the KAPA SYBR® FAST Universal 2X qPCR Master Mix. The Drosophila qPCR 
reaction used iQ SYBR. qPCR primers are listed within the Supplementary Table 1. qRT-
PCR was run and analyzed on the CFX96 Real-Time PCR Detection System (BIORAD), 
with all target gene expression levels normalized to β-actin mRNA levels (human and M. 
musculus), FBA1 mRNA levels (S. cerevisiae) or RpL32 mRNA levels (D. melanogaster).
Lentivirus production
Lentiviral particles were generated by transfecting 293T cells with the pSB700 sgRNA 
expression plasmid (with cerulean reporter) and the psPAX2 & pMD2.G (Addgene #12260 
and #12259) packaging vectors at a ratio of 4:3:1, respectively. Viral supernatants were 
collected 48–72h following transfection and concentrated using the PEG Virus Precipitation 
Kit (BioVision) according to the manufacturer’s protocol.
iPSC culture and dCas9-AD cell line generation
PGP1 iPS cells were obtained from the Coriell Institute Biorepository (GM23338) and 
maintained on matrigel (Corning) coated tissue culture plates in mTeSR1 Basal medium 
(Stemcell technologies). To generate stable iPS dCas9-AD expressing cell lines, 
approximately 5x10^5 cells were nucleofected with 1.5μg of dCas9-AD piggy-bac 
expression vector and 340ng of transposase vector (System Biosciences) using the Amaxa 
P3 Primary Cell 4D-Nucleofector X Kit (Lonza), program CB-150. Following 
electroporation, cells were seeded onto 24-well matrigel-coated plates in the presence of 
10uM ROCK inhibitor (R&D systems) and allowed to recover for two days before 
expanding to 6-well plates in the presence of 20ug/ml hygromycin to select for a mixed 
population of dCas9-AD integrant containing cells.
iPSC transduction and neural induction
iPS dCas9-AD cell lines were transduced with lentiviral preparations containing 30 gRNAs, 
targeted against either NEUROD1 or NGN2, one day after seeding onto matrigel coated 
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plates. Transduced cells were expanded and then sorted for the top 15% of cerulean positive 
cells (pSB700 gRNA expression). Sorted gRNA containing dCas9-AD iPS cell lines were 
seeded in triplicates onto matrigel coated 24-well plates with mTeSR + 10uM ROCK 
inhibitor, either in the presence or absence of 1ug/ml of doxycycline. Fresh mTeSR medium 
+ or − doxycycline was added every day for 4 days, at which cells were analyzed by light 
microscopy, immunofluorescence and harvested for qRT-PCR analysis.
Immunostaining of Cas9 iNeurons
All steps for staining were performed at room temperature. Samples were washed once with 
PBS then fixed with 10% formalin (Electron Microscopy Sciences) for 20 min followed by 
permeabilization with 0.2% Triton X-100/PBS for 15 min. Samples were then blocked with 
8% BSA for 30 min followed by staining with primary antibodies diluted into 4% BSA. 
Staining was performed for either 3h with anti-beta III eFluor 660 conjugate (eBioscience, 
catalog no. 5045-10, clone 2G10-TB3) or 1h with anti-neurofilament 200 (Sigma, catalog 
no. N4142), both at a 1:500 dilution. Samples were then washed 3 times, 5 minutes each, 
with 0.1% tween/PBS, followed by one wash with PBS. For neurofilament 200 staining, a 
secondary donkey anti-rabbit Alexa Fluor 647 (Life Sciences) antibody was added at a 
1:1000 dilution in 4% BSA for 1h. Samples were again washed as previously mentioned 
then stained with nucBlue [Hoechst 33342] (Life Sciences) for 5 min.
Image acquisition and analysis of Cas9 iNeurons
24-well plates stained for NucBlue and neuronal markers, were imaged with a 10x objective 
on a Zeiss Axio Observer Z1 microscope. Zen Blue software (Zeiss) was used to program 
acquisition of 24 images per well. Total cell (NucBlue) and iNeuron (Beta III tubulin or 
Neurofilament 200) counts were quantified for each image using custom Fiji and Matlab 
scripts and used to determine the percentage of iNeurons per well by the formula: (number 
of Beta III positive cells/number of nucBlue cells) × 100. In preparation for publication, 
individual channels were composited and pseudocolored, with equal adjustments across 
samples and controls, in Fiji.
Statistical analysis
All statistical comparisons are two-tailed t-tests calculated using the GraphPad Prism 
software package (Version 6.0 for Windows. GraphPad Software, San Diego, CA). All 
sample numbers listed indicate the number of biological replicates employed in each 
experiment.
Code availability
Custom Fiji and Matlab scripts utilized in analyzing iPS cell differentiation are available 
upon request.
Reproducibility
Throughout our study, we employ a sample size which is frequently used for similar kinds 
of experiments. No data were excluded from any of our analysis. No randomization was 
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employed and blinding was not used except in iNeuron image analysis where the scientist 
quantifying each of the conditions was blind to the sample type.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Gene activation using VPR. (a) RNA expression of individual targets in HEK 293T cells 
transfected simultaneously with three or four gRNAs targeting the indicated genes along 
with the labeled dCas9-activator construct. Negative controls (Neg.) were transfected with 
indicated guide RNAs alone. Data are shown as the mean ± s.e.m (n = 3 independent 
transfections). For *, P = < 0.05 (n.s. = not significant). Comparison of dCas9-VP64 vs. 
dCas9-VPR, for all genes, is significant (P = <0.0011). (b) RNA expression during 
multiplex activation of the indicated four endogenous gene targets. Data are shown as the 
mean ± s.e.m (n = 3 independent transfections). For *, P = < 0.05. Comparison of dCas9-
VP64 vs. dCas9-VPR, for all genes, is significant (P = <0.0022).
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Figure 2. 
dCas9-mediated iPSC neuronal differentiation using VPR. (a) Pseudocolored 
immunofluorescence images for NucBlue (blue, total cells) and beta III tubulin (red, 
iNeurons) four days after doxycycline induction. Images are representative of biological 
triplicates (separately seeded wells). Scale bar represents 100 μm. (b) Immunofluorescence 
quantification and comparison of iNeurons generated by either dCas9-VP64 or dCas9-VPR. 
Data is shown as the mean ± s.e.m. (n = 3 independent platings of stable cell lines, with each 
replicate being an average of 24 separate images). For *, P = < 0.001. (c) qRT-PCR analysis 
of mRNA expression levels of NGN2 and NEUROD1 in dCas9-AD iPS cell lines. Data is 
normalized to dCas9-VP64 cells and shown as the mean ± s.e.m. (n = 2 independent platings 
of each stable cell line). For *, P = < 0.05.
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